Integra LifeSciences generates annual revenues hovering around one billion four hundred million dollars to one billion five hundred million dollars. The company's top-line financial performance is driven by its two core operational segments, Codman Specialty Surgical and Tissue Technologies, which distribute medical devices, surgical instruments, and regenerative wound care solutions to hospital networks and ambulatory surgical centers worldwide.
The primary product categories driving Integra LifeSciences' commercial revenue include Codman specialty surgical tools, dural repair membranes, precision neurosurgery equipment, advanced tissue ablation systems, and regenerative wound care solutions...
Integra LifeSciences completed a landmark acquisition of Johnson & Johnson's Codman Neurosurgery business for approximately one billion and forty-five million dollars.
Financial equity research analysts covering Integra LifeSciences maintain a generally neutral consensus rating, with most 12-month average price targets hovering around the eighteen to nineteen dollar range.
Integra LifeSciences operates through several key domestic and international subsidiaries and operating units that handle its specialized manufacturing, global distribution, and regional commercial activities.
Financial equity research analysts covering Integra LifeSciences maintain consensus 12-month average price targets generally clustering in the upper teens range.
Integra products are utilized extensively across neurosurgery, reconstructive surgery, and advanced wound care applications.
Employee reviews and corporate workplace assessments for Integra LifeSciences generally highlight a collaborative culture, meaningful engagement within the mission-driven medical technology sector, and opportunities for professional growth in enginee...
Stuart M. Essig serves as the President and Chief Executive Officer of Integra LifeSciences, having stepped back into the executive leadership role to guide the company through its next strategic phase.
Compensation packages for Vice President-level executives at major medical technology firms like Integra LifeSciences typically comprise a substantial base salary, annual performance-based cash bonuses, and long-term equity incentives such as restric...
Smith+Nephew did not acquire the entire Integra LifeSciences enterprise, but it did successfully complete the acquisition of Integra's Extremity Orthopaedics business for two hundred and forty million dollars in cash.
Integra LifeSciences Holdings Corporation is a publicly traded enterprise listed on the NASDAQ stock exchange under the ticker symbol IART, meaning its ownership is broadly distributed among thousands of institutional asset management firms, mutual f...
Integra LifeSciences exhibits steady strategic evolution and product pipeline expansion, though its financial growth has experienced short-term fluctuations due to targeted manufacturing facility optimizations, quality system remediation efforts, and...
Integra LifeSciences operates as a mid-cap medical technology organization with an annual revenue generation hovering around one billion four hundred million to one billion five hundred million dollars.
The global corporate headquarters of Integra LifeSciences is situated in Princeton, New Jersey, United States.
The executive leadership team of Integra LifeSciences features seasoned professionals with extensive experience in the medical device and healthcare industries. Stuart M.
Evaluating whether Integra LifeSciences is a solid corporate entity involves weighing its strong market positioning in neurosurgery and regenerative wound care against ongoing operational challenges and quality remediation execution.
Integra LifeSciences Holdings Corporation is a publicly traded enterprise listed on the NASDAQ stock exchange under the ticker symbol IART, meaning its ownership is broadly distributed among thousands of institutional asset management firms, mutual f...
Integra LifeSciences Holdings Corporation is a prominent multinational medical technology enterprise specializing in the research, development, manufacturing, and distribution of innovative surgical instruments, neurosurgical devices, and advanced ti...
The corporate headquarters of Integra LifeSciences is officially located in Princeton, New Jersey, United States.
Integra LifeSciences has implemented targeted workforce reductions and operational restructuring initiatives in response to facility optimizations and quality system remediation programs.
Whether Integra LifeSciences represents a favorable stock purchase depends heavily on an investor's risk tolerance and time horizon.
Integra LifeSciences specializes in a diverse portfolio of advanced medical technologies, surgical instruments, and tissue regeneration products designed for neurosurgery, reconstructive surgery, and general wound care.
Integra LifeSciences employs approximately 4,300 to 4,500 personnel globally across its corporate headquarters, research and development laboratories, and manufacturing facilities.
Integra LifeSciences Holdings Corporation is a publicly traded enterprise listed on the NASDAQ stock exchange under the ticker symbol IART, meaning its ownership is broadly distributed among thousands of institutional asset management firms, mutual f...
The total corporate market capitalization of Integra LifeSciences fluctuates continuously during active market trading sessions based on its share price and total outstanding common stock, generally resting in the range of one billion to one and a ha...